Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danusertib - Nerviano Medical Sciences

Next Previous
Search
Drug Profile

Danusertib - Nerviano Medical Sciences

Alternative Names: NMS Aurora inhibitor; PHA-739358

Latest Information Update: 28 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer National Cancer Institute (USA); Nerviano Medical Sciences
  • Class Antineoplastics; Benzamides; Pyrazoles; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic myeloid leukaemia; Prostate cancer
  • No development reported Neuroblastoma; Precursor cell lymphoblastic leukaemia-lymphoma; Small cell lung cancer
  • Discontinued Multiple myeloma; Solid tumours

Most Recent Events

  • 28 Jan 2022 No recent reports of development identified for preclinical development in Neuroblastoma in Italy
  • 28 Jan 2022 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in Italy
  • 16 Jan 2020 Phase-II development is ongoing (Nerviano pipeline, January 2020)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top